Today in a hearing in the Senate Committee on Health, Education, Labor and Pensions, U.S. Senator Josh Hawley (R-Mo.) secured a commitment from Jim O’Neill – President Trump’s nominee to serve as Deputy Secretary of Health and Human Services – to conduct an updated safety review on the chemical abortion drug mifepristone if he were confirmed. The promise comes on the heels of a new study showing that 1 in 10 women who take the drug suffer from adverse health effects.
O’Neill agreed with Senator Hawley that the new study warranted review, for the health and safety of women across the nation.
“The Secretary [Robert F. Kennedy Jr.] has pledged to do a safety review of mifepristone, and I strongly support that view,” O’Neill said.
Senator Hawley has been a staunch advocate for women across the nation, from introducing legislation to reinstate safeguards on mifepristone that the Biden Administration eliminated to urging the Department of Justice to reconsider its position in Missouri’s mifepristone litigation.
###